"Aspirin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
| Descriptor ID |
D001241
|
| MeSH Number(s) |
D02.455.426.559.389.657.410.595.176
|
| Concept/Terms |
Aspirin- Aspirin
- Acetylsalicylic Acid
- Acid, Acetylsalicylic
- 2-(Acetyloxy)benzoic Acid
|
Below are MeSH descriptors whose meaning is more general than "Aspirin".
Below are MeSH descriptors whose meaning is more specific than "Aspirin".
This graph shows the total number of publications written about "Aspirin" by people in this website by year, and whether "Aspirin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 2 | 3 |
| 1995 | 0 | 3 | 3 |
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 1 | 2 |
| 1998 | 2 | 1 | 3 |
| 1999 | 2 | 2 | 4 |
| 2000 | 0 | 1 | 1 |
| 2001 | 2 | 5 | 7 |
| 2002 | 2 | 1 | 3 |
| 2003 | 8 | 3 | 11 |
| 2004 | 5 | 4 | 9 |
| 2005 | 5 | 6 | 11 |
| 2006 | 5 | 7 | 12 |
| 2007 | 4 | 5 | 9 |
| 2008 | 3 | 2 | 5 |
| 2009 | 8 | 5 | 13 |
| 2010 | 6 | 2 | 8 |
| 2011 | 5 | 3 | 8 |
| 2012 | 5 | 6 | 11 |
| 2013 | 6 | 3 | 9 |
| 2014 | 6 | 5 | 11 |
| 2015 | 6 | 2 | 8 |
| 2016 | 8 | 3 | 11 |
| 2017 | 12 | 3 | 15 |
| 2018 | 10 | 8 | 18 |
| 2019 | 4 | 2 | 6 |
| 2020 | 5 | 12 | 17 |
| 2021 | 9 | 10 | 19 |
| 2022 | 5 | 5 | 10 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aspirin" by people in Profiles.
-
Placental growth factor at 24-28?weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial. Acta Obstet Gynecol Scand. 2024 Nov; 103(11):2273-2280.
-
Aspirin vs P2Y12 Inhibitors: A Few Questions Unanswered. J Am Coll Cardiol. 2024 Jan 02; 83(1):e7.
-
The underutilization of preventive cardiovascular measures in patients with cancer: an analysis of the Behavioural Risk Factor Surveillance System, 2011-22. Eur J Prev Cardiol. 2023 09 20; 30(13):1325-1332.
-
Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trial. BJOG. 2024 Feb; 131(3):334-342.
-
Development and Validation of a Novel 1-year Mortality Risk Score That Includes the Use of Antithrombotic in Patients With Overt Gastrointestinal Bleeding. J Clin Gastroenterol. 2023 08 01; 57(7):700-706.
-
Aspirin Discontinuation in Pregnancies at High Risk of Preterm Preeclampsia-Reply. JAMA. 2023 06 13; 329(22):1988-1989.
-
Aspirin and immunotherapy: a Faustian bargain? J Clin Invest. 2023 05 01; 133(9).
-
Association of Clinician Practice Ownership With Ability of Primary Care Practices to Improve Quality Without Increasing Burnout. JAMA Health Forum. 2023 03 03; 4(3):e230299.
-
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial. JAMA. 2023 02 21; 329(7):542-550.
-
The effects of heparin, aspirin, and maternal clinical factors on the rate of nonreportable cell-free DNA results: a retrospective cohort study. Am J Obstet Gynecol MFM. 2023 03; 5(3):100846.